8-K: BiomX Announces Third Quarter 2024 Results and Provides Clinical Program Updates

BiomX reports completion of patient enrollment for its BX211 DFO trial and a delay in the BX004 CF trial results, alongside its Q3 2024 financial results.

Summary

• BiomX has completed patient enrollment for the Phase 2 trial of BX211, a treatment for Diabetic Foot Osteomyelitis (DFO), with topline results expected in Q1 2025.
• The Phase 2b study for BX004, a treatment for Cystic Fibrosis (CF), has been delayed due to manufacturing issues and is now expected to report topline results in the first half of 2026.
• The company received additional non-dilutive funding from the US Defense Health Agency (DHA) for the DFO program.
• BiomX's cash balance was $24.7 million as of September 30, 2024, compared to $30.7 million at the end of 2023.
• Research and development expenses increased to $7.3 million in Q3 2024 from $5.6 million in Q3 2023, primarily due to clinical trial preparations and the acquisition of Adaptive Phage Therapeutics (APT).
• General and administrative expenses rose to $3.2 million in Q3 2024 from $2.2 million in Q3 2023, mainly due to the APT acquisition.
• The company recorded a net income of $9.6 million in Q3 2024, compared to a net loss of $7.9 million in Q3 2023, primarily due to changes in the fair value of warrants.
• Net cash used in operating activities for the nine months ended September 30, 2024, was $30.7 million, compared to $15.0 million for the same period in 2023.
• BiomX estimates its current cash reserves will fund operations into the fourth quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive progress in the BX211 program but a significant delay in the BX004 program. The financial results show a net income, but this is largely due to warrant valuation changes, not core operations. The delay and increased expenses temper the positive aspects.

Positives

• Patient enrollment for the BX211 Phase 2 trial is complete, indicating progress in the DFO program.
• Additional non-dilutive funding from the DHA supports the advancement of the BX211 trial.
• Positive safety and efficacy data from the Phase 1b/2a trial of BX004 in CF were presented at scientific conferences.
• The company reported a net income of $9.6 million for Q3 2024, a significant improvement from the net loss in the same period last year.
• BiomX estimates its cash reserves are sufficient to fund operations into the fourth quarter of 2025.

Negatives

• The Phase 2b study for BX004 in CF has been delayed due to manufacturing issues, pushing the topline results to the first half of 2026.
• The company's cash balance decreased from $30.7 million at the end of 2023 to $24.7 million as of September 30, 2024.
• Research and development expenses increased to $7.3 million in Q3 2024, indicating higher operational costs.
• General and administrative expenses also increased to $3.2 million in Q3 2024, primarily due to the APT acquisition.
• The company recognized a goodwill impairment expense of $801 thousand in Q3 2024 related to the APT acquisition.
• Net cash used in operating activities for the nine months ended September 30, 2024, was $30.7 million, compared to $15.0 million for the same period in 2023.

Risks

• The delay in the BX004 Phase 2b study could impact the timeline for commercialization and investor confidence.
• The company's cash reserves are decreasing, although they are projected to last into Q4 2025.
• Increased research and development and general and administrative expenses could strain the company's finances.
• The goodwill impairment expense indicates potential issues with the valuation of the APT acquisition.
• The company is subject to risks inherent in pharmaceutical research and development, including adverse results in clinical trials and regulatory hurdles.

Future Outlook

BiomX anticipates reporting topline results for the BX211 Phase 2 trial in Q1 2025 and for the BX004 Phase 2b study in the first half of 2026. The company estimates its current cash reserves will fund operations into the fourth quarter of 2025.

Management Comments

• We continue to be encouraged by the progress in diabetic foot osteomyelitis (DFO), having achieved an important milestone by completing patient enrollment for the BX211 program, said Jonathan Solomon, BiomXs Chief Executive Officer.
• We remain on track to share topline (through Week 13) Phase 2 results of BX211 in the first quarter of 2025.

Industry Context

BiomX is operating in the competitive field of phage therapy, targeting chronic diseases with unmet needs. The company's focus on personalized and engineered phage treatments positions it to address specific bacterial infections. The delay in the BX004 trial highlights the challenges in manufacturing and clinical development within this sector.

Comparison to Industry Standards

• The completion of enrollment for the BX211 Phase 2 trial is a positive milestone, aligning with typical timelines for clinical trials in the biotech industry.
• The delay in the BX004 Phase 2b trial is not uncommon in drug development, where manufacturing issues can cause setbacks. Companies like Spero Therapeutics and Achaogen have faced similar challenges in bringing novel anti-infectives to market.
• The increase in R&D expenses is typical for a clinical-stage company advancing multiple programs. Companies like Paratek Pharmaceuticals and Nabriva Therapeutics have also seen similar increases in R&D spending as they progress through clinical trials.
• The net income of $9.6 million is unusual for a company at this stage, and is primarily due to the change in the fair value of warrants, not from core operations. This is not a typical metric for comparison with other biotech companies.
• The cash runway into Q4 2025 is a critical metric, and is comparable to other companies in the sector. Companies like Cidara Therapeutics and Iterum Therapeutics have also focused on extending their cash runway through various financing activities.

Stakeholder Impact

• Shareholders may be concerned about the delay in the BX004 program and the decrease in cash reserves.
• Employees may be affected by the changes resulting from the APT acquisition.
• Patients with DFO may benefit from the progress in the BX211 program.
• Patients with CF may experience a delay in the availability of the BX004 treatment.

Next Steps

• BiomX will report topline results for the BX211 Phase 2 trial in Q1 2025.
• BiomX will report topline results for the BX004 Phase 2b study in the first half of 2026.
• The company will continue to advance its clinical programs and manage its cash resources.

Key Dates

Keywords

BiomX, phage therapy, Diabetic Foot Osteomyelitis, Cystic Fibrosis, BX211, BX004, clinical trials, financial results, reverse stock split, non-dilutive funding